• About Us
    • Company Overview
    • Leadership
    • Locations
  • Nelmastobart
    • Novel Immune-Checkpoint BTN1A1
    • Main Indications
  • R&D
    • Research Achievements
    • Pipeline
  • IR
    • Public Disclosure Information
    • Stock Price Information
    • IR Materials
  • PR
    • Press Release
    • Notices
  • Careers
    • Careers
  • Partnership
    • Partnership
ENG
  • KOR
  • ENG
  • About Us
    • Company Overview
    • Leadership
    • Locations
  • Nelmastobart
    • Novel Immune-Checkpoint BTN1A1
    • Main Indications
  • R&D
    • Research Achievements
    • Pipeline
  • IR
    • Public Disclosure Information
    • Stock Price Information
    • IR Materials
  • PR
    • Press Release
    • Notices
  • Careers
    • Careers
  • Partnership
    • Partnership
R&D
STCube is dedicated to developing precision-driven immunotherapies,
bringing new hope to more cancer patients.
  • Research Achievements
  • Pipeline
Research Achievements
  • Research Achievements
  • Pipeline
Research Achievements
  • Home
  • R&D
  • Research Achievements
  • Academic Papers
  • Poster Presentations
  • Journal for ImmunoTherapy Cancer. 2024 Mar
    BTN1A1 is a novel immune checkpoint mutually exclusive to PD-L1
  • Gastroenterology. 2021 Mar
    Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice
  • Cancer Research. 2020 Jun
    Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity
  • Cancer Cell. 2018 Feb
    Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
1

2201, Trade Center Trade Tower, 511 Yeongdong-daero, Gangnam-gu, Seoul, Republic of Korea

Tel : +82-2-551-3370

Copyright by STCube All Rights Reserved.